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Introduction
Dopamine receptors are members of a large su-
perfamily of receptor proteins coupled to heterotri-
meric guanine nucleotide-binding regulatory proteins
(G proteins). They are involved in motor control, neu-
roendocrine regulation, cognition and emotion. These
receptors are crucial targets in the therapy of schizo-
phrenia, Parkinson's disease, Tourette's syndrome,
tardive dyskinesia and Huntington's disease (1).
On the basis of their biochemical and pharma-
cological properties five distinct dopamine receptors
(DA-Rs) have been isolated, characterized and subdi-
vided into two subfamilies, D1- and D2-like. The for-
mer comprises D1 and D5 receptors, while the latter
includes D2, D3, and D4 subtypes (2). Further diversi-
ty in the human dopamine receptors can be achieved
by alternative RNA splicing and by the existence of
expressed polymorphic sequences.
Two isoforms of the dopamine D2 receptor have
been characterized, D2L (long) and D2s (short), gene-
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Summary: In order to find the essential structural motif of the D2L dopamine receptor necessary for the
interaction with a-subunit of Gi1 protein, four fragments of the third cytoplasmic loop (CPL3) of this receptor were
cloned, expressed in E. coli and purified. After that, fusion proteins with glutathione-S-transferase (GST) were
prepared and the interactions quantified by a colorimetric assay for GST activity determination. The presence of
D2L-CPL3 fragment-Gia1 complexes was detected by SDS-polyacrylamide gel electrophoresis (PAGE). Kd values
for the interaction of the three fragments with Gia1 were similar and in nmol/L range of concentrations, while the
peptide representing the insert in the long form of the dopamine D2 receptor expressed about 10-fold lower bind-
ing affinity. These results could serve to design new therapeutic agents that might act at the level of receptor/G
protein interaction rather than at the level of ligand-receptor binding.
Key words: Dopamine D2L receptor, third intracellular loop, synthetic peptide, receptor/G protein coupling.
* Abbreviations: Gi and Go-guanine nucleotide-binding proteins as
classified by Gilman (3); Ga-a-subunit of denoted protein; D2L,
D2S-dopamine receptor, long and short variant, subfamily 2;
D2L-CPL3-the third intracellular loop of dopamine D2L receptor;
D2L-CPL3 fragment-GST-the D2L-CPL3 fragment and GST fu-
sion protein.
rated by alternative splicing from the same gene. They
differ by an in-frame insert of 29 amino acids specific
to D2L within the third cytoplasmic loop of the recep-
tor (4). Expression of two isoforms is tissue-specific
(5), D2L appearing to be the major isoform (6, 7).
Analysis with subtype-specific antibodies against both
the D2S and long isoforms have shown a unique com-
partmentalization between these two isoforms in the
primate brain. Splice variants of the dopamine D2
receptor are differentially distributed and possess dis-
tinct functions. The strategic localization of the D2S
isoform in dopaminergic cell bodies and axons strong-
ly suggests that this isoform is the likely dopamine
autoreceptor, whereas the D2L isoform is primarily a
postsynaptic receptor (8).
D1 receptors activate adenylyl cyclase and are
coupled to Gs regulatory protein. In contrast, activa-
tion of D2 receptors results in various responses inclu-
ding inhibition of adenylyl cyclase and phosphatidyli-
nositol turnover, increase in K+ channel activity and
inhibition of Ca2+ mobilization (6). All these different
signalling pathways involve the activation of the Gi/Go
family of G proteins (7, 9). First, Gi2 appeared to cou-
ple selectively to the D2 receptor with ∼10-fold higher
affinity than any other tested Gi subtype (10). Later,
the same authors have shown that alternative splice
forms of D2 dopamine receptor are able to signal to
different Gi proteins (11). Specifically, it seems that 29
amino acid insert of D2L confers interaction selectivity
for Gi2 (4). Preferential interaction of the D2S isoform
with Gi1 than Gi2 was demonstrated (7) that was con-
sistent with previous results. Using different experi-
mental approach other authors demonstrated an
essential difference in coupling of dopamine D2L and
D2S receptors to G proteins (12, 13). As the two forms
of dopamine D2 receptors differ within the third cyto-
plasmic loop, the data presented support the data on
the importance of this domain in receptor coupling to
G proteins, as well as the functional significance of the
29-amino acid insert in the third loop of D2L (4).
Comparison of the D2 receptor gene in humans and
mice demonstrates that its sequence and splicing
events have been highly conserved through the evolu-
tion. This might indicate that the presence of the two
isoforms and their selective interaction with different G
proteins represent an essential feature of the dopami-
ne D2 receptor function in vivo (4).
Cerebral D2 dopamine receptor is the target for
pharmaceuticals used to alleviate the main symptoms
of schizophrenia and seems to play an essential role in
the dopaminergic control of physiological functions
(14). All currently used antipsychotic agents have anti-
dopaminergic properties, but the side effects associat-
ed with their use suggest that therapeutic alternatives
are necessary (15). Compounds that interact directly
with G proteins can mimic the receptor/G protein
interaction or can block the activation of G proteins by
receptors (16). To date, virtually all known antagonists
of these receptors share the common property of
blocking access of the ligand to the receptor. Alterna-
tive strategy for designing receptor antagonists might
be to block the interaction of the receptor with the G
protein (17). The third intracellular domain (3i) of G
protein coupled receptors plays a major role in the
activation of G proteins. Alterations in this region of
the receptor can affect receptor/G protein coupling
efficiency and specificity. Coexpression of the 3i loop
with its homologous receptor resulted in specific inhi-
bition of agonist-stimulated second messenger gener-
ation mediated via homologous receptor (17). This
suggests that peptides derived from a G protein-cou-
pled receptor might serve as antagonists of receptor/G
protein interactions (18). Inhibition could occur by se-
veral mechanisms, such as competition for Ga sub-
units of a hormone-receptor complex and the free 3i
loop of the receptor, or interaction between the 3i loop
peptide and the intracellular domains of the parent
receptor thus disrupting receptor conformation and
keeping it inactive (17). The finding that: a) the 3i do-
main peptide provoked inhibition of homologous re-
ceptor signalling was surmountable at high receptor
density and b) that weak enhancement of basal sec-
ond messenger generation in cells expressing the 3i
domain alone is detected (18) led to conclusion that 3i
domain peptides act as weak partial agonists at the
level of the G protein. Partial DA-receptor agonists
should be eminently suitable for stabilizing neurotrans-
mitter function. Such agents can also be described as
mixed agonist-antagonists, implying that they serve as
an agonist when the level of endogenous full agonist is
low at receptor sites and as an antagonist when this
level is high (15). The specificity with which the 3i
domain peptides inhibit receptor-mediated signalling
suggests the feasibility of developing drugs that might
exert inhibition at the level of receptor/G protein inter-
action rather than at the level of ligand-receptor bind-
ing (18). Therefore, finding domains essential for this
interaction could be of great significance in future de-
sign of pharmacologically active compounds.
Materials and methods
Plasmid DNA encoding hD2L CPL3 (pCD3hD-
2lPDX) was kindly donated by Dr. O. Civelli (Oregon
Health Sci. Univ., Portland, OR, U.S.A.). Plasmid pQE-
60, encoding Gia1, was a generous gift of Dr Chris-
tiane Kleuss (Freie Unive. Berlin, Inst. Pharmacol.,
Berlin, Germany). Plasmids encoding fragments of
D2L-CPL3 cloned into pGEX-2T (fr1: 211-241. a.a.,
fr3-211-277. a.a. and fr4-271-373. a.a.) were previ-
ously constructed in our laboratory by Ms Marija Bac-
kovi} and Ms Bosiljka Tasi} (data not published).
The other materials were obtained from the fol-
lowing commercial sources: expression vector pGEX-
2T, restriction endonucleases, T4 DNA ligase, alkaline
phosphatase and T4 polynucleotide kinase ’ Biolabs-
New England, U.S.A.; PfuDNA polymerase ’ Stratage-
ne, La Jolla, CA, U.S.A.; DNAse ’ Boehringer, Man-
10 Jugoslov. Med. Biohem. 2002.; 21 (1)
cheim, Germany; ATP, GDP, phenylmethylsulfonylflu-
oride (PMSF), ampicillin ’ Sigma Chem.Co., St. Louis,
MO, U.S.A.; glutathione (GSH) and Na-deoxycholate ’
Merck, Darmstadt, Germany; Glutathione-Sepharose
’ Pharmacia LKB, Uppsala, Sweden; bactopeptone,
yeast extract and bacto agar ’ Difco Laboratories, De-
troit, MI, U.S.A.; CDNB ’ Squib-Bristol. All other che-
micals were of analytical grade of purity.
Cloning of the insert of the third intracellular
loop of the human dopamine D2L receptor into
pGEX-2T ’ Standard molecular biology procedures
were used for DNA manipulations (19). The insert of
the CPL3 of the hD2L receptor was amplified by poly-
merase chain reaction (PCR). To obtain insert of the
CPL3-D2L the following pair of primers was used in
PCR containing plasmid DNA encoding hD2L CPL3 as
a template: forward-5'-GCGC GGA TCC CAC CTG
AGG GCT CCA CTA AAG-3' and reverse-5'-GCCG
GAA TTC CTG GGC TCG CCG GGC AGC CTC-3'. The
PCR product was cut with BamHI and EcoRI restriction
enzymes and cloned into BamHI-EcoRI sites of the
prokaryotic expression plasmid pGEX-2T. The validity
of the DNA constructs was confirmed by automated
fluorescent DNA sequencing using reagents and
instruments from Applied Biosystems (California,
USA).
Expression and purification of the D2L-CPL3
fragment fusion proteins ’ E. Coli BL21 was mainta-
ined and transformed with pGEX-2T-D2L-CPL3 frag-
ment using CaCl2 method (19). The cells were grown
in LB medium supplemented with ampicillin and ex-
pression was induced with iso-propylthiogalactoside
(IPTG) as described by Simonovi} et al. (20, 21). D2L-
CPL3 fragment-GST fusion proteins were purified
using GSH-Sepharose (20, 21). 
Expression and purification of His-Ga protein
’ This was done as described by Lee et al. (22).
Ga-D2L-CPL3 fragments-GST His-Bind Resin
Assay ’ This was performed as suggested by Simono-
vi} et al. (20).
Assay for detection of D2L-CPL3 fragment-Ga
complexes on SDS-PAGE ’ Glutathione-Sepharose
Resin was washed with buffer (10 mmol/L Tris, pH-
7.4, 0.1% BSA) by repeated centrifugation (1000 rpm,
1 min) and 10 mg of each GST-fusion protein in the
same buffer (total volume ∼90 mL) was loaded onto
∼40 mL of equilibrated 50% resin suspension. The
resin was incubated (30 min, 22 °C, constant shaking),
double washed with ice-cold buffer, to remove unbo-
und proteins. Gia1 solution (20 mg, in ∼90 mL of buf-
fer containing 10 mmol/L Tris-HCl, pH 7.4, 0.1% BSA,
1.0 mmol/L GDP and 5 mmol/L MgCl2) was added
and the incubation continued for 60 min. Unbound
protein was removed by successive washing with ice-
cold buffer (10 mmol/L Tris-HCl, pH 7.4, 120 mmol/L
NaCl; 0.1% Triton X-100). The agarose beads were
boiled in sample buffer, subjected to SDS/PAGE and
the gel was silver stained (23). The controls containing
only Ga without GST-CPL3 fragment and only GST-
CPL3 fragment without Ga, served to distinguish bind-
ing of Ga to CPL3 fragment from non-specific binding
of Ga to the resin.
Data analysis ’ Saturation binding data were
analyzed and graphically displayed by one site binding
curve fitting using the Micorcal Origin 6.0 program
which was also employed to calculate Kd values.
Miscellaneous ’ Proteins were determined after
Bradford et al. (24) using bovine serum albumin (BSA)
as a reference. Degree of protein purification was
checked by SDS-PAGE as described by Laemmli (25).
Results
Four fragments of the D2L-CPL3: fr1-211.-
241.a.a., fr2-235.-277.a.a.(insert of D2L-CPL3), fr3-
211.-277.a.a. and fr4-271.-373.a.a. were successfully
cloned and expressed. Upon purification they were
obtained in soluble form in the yield of 0.66, 0.86,
1.17, 0.17 mg/L, respectively. Various concentrations
of Ga-proteins were immobilized on His-Bind Resin
and titrated by D2L-CPL3 fragment-GST fusion pro-
tein. The results presented as saturation binding cur-
ves are shown in Figure 1–4. Concentration of Gia1-
His-GDP ranged from 0.0136’16.26 nmol/L. The
interactions were estimated by colorimetric assay for
GST activity determination. Representative curves are
shown. Kd values were calculated from saturation
binding curves. The results are the mean values of
“SEM from at least 3 experiments done in triplicate.
Kd values for the interactions of D2L-CPL3 fragments-
GST and His-tagged Ga-GDP proteins calculated
from saturation binding curves are inserted in Figure
1–4. As seen, all Kd values were in nmol/L range of
concentrations being rather close for fragments 1, 3
and 4, while that of fragment 2 (peptide representing
insert in the long form of the dopamine D2 receptor)
was about 10-fold higher. 
The appearance of the band representing Gia1
on SDS-PAGE slab gel (Figure 5) was an alternative
proof for the interaction of the Ga subunit with all four
fragments of D2L-CPL3 examined in the present study.
Discussion
Several authors used a strategy of coexpression
of peptides from D2L-CPL3 with its homologous re-
ceptor in vivo (26, 27) and showed that regions flan-
king each extremity of the loop are fundamental for
coupling of the receptor to G proteins. Insert in the
long form of the dopamine D2 receptor doesn't seem
to affect functional coupling of the D2L receptor to G
protein (26), but plays a critical role in the selectivity of
these interactions (4). Since it is located outside the
regions responsible for interactions with G protein, it
was hypothesized that it might affect coupling speci-
ficity indirectly by incorporating novel stretch of
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residues in CPL3 and thus interrupting a putative a-
helical structure, generating a novel structure that
confers interaction selectivity for Gia2 (4). Quantitative
estimation of these interactions hasn't been performed
previously.
Our results are in accordance with the data of
several authors (26, 27) demonstrating that the NH2-
and COOH- terminal portions of the third cytoplasmic
loop of the dopamine D2 receptor do interact directly
with a subunit of G protein. Further, we showed that
there is no particular domain in the D2L-CPL3 respon-
sible for this interaction, as judged by a high affinity
binding of all fragments except one, representing the
insert in the long form of the D2 receptor, which also
interacts with Ga, but with about 10-fold lower binding
affinity. This high binding affinity suggests that selec-
tivity was achieved by direct contact of insert with G
protein rather than inducing changes in conformation
of other parts of CPL3.
The identification of domains crucial for the in-
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Figure 1.   Saturation binding curve of Gia1-His-GDP
form interaction with FR1 (211.-241. a.a.)
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Figure 2.   Saturation binding curve of Gia1-His-GDP
form interaction with FR2 (235.-277. a.a.)
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Figure 3.   Saturation binding curve of Gia1-His-GDP
form interaction with FR3 (211.-277. a.a.)
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Figure 4.   Saturation binding curve of Gia1-His-GDP
form interaction with FR4 (271.-373. a.a.)
A
34
0
0.06
0.05
0.04
0.03
0.02
0.01
0.00
’2    0     2     4     6     8    10   12   14   16    18
Concentration of His-Gai1, nmol/L
Kd = 0.3 ± 0.2 nmol/L
teraction with G protein, and qualitative and quantita-
tive estimation of these interactions could be useful in
developing new therapeutic agents that would behave
as weak partial agonists at the level of receptor/G pro-
tein interaction. However, peptides themselves are un-
likely to be suitable as therapeutics because of prob-
lems with peptidases and inability to penetrate through
target cell membrane. Solutions to these problems
might be found in the synthesis of peptidomimetics ’
non-peptide analogues of similar structure that could
mimic peptide activities or introduction of these do-
mains to target cells by gene therapy (28).
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Figure 5.   SDS-PAGE analyses of interactions of 
GST-fusion proteins with Gia1-His-GDP. As standard 
we used 10 kDa Protein Ladder (Gibco BLR). 
Gel was silver stained.
1 ’ FR1-GST
2 ’ FR2-GST
3 ’ FR3-GST
4 ’ FR4-GST
5 ’ Gia1
6 ’ RESIN+Gia1
7 ’ STANDARD
8 ’ RESIN+FR1+Gia1
9 ’ RESIN+FR1
10 ’ RESIN+FR2 +Gia1
11 ’ RESIN+FR2
12 ’ RESIN+FR3+Gia1
13 ’ RESIN+FR3
14 ’ RESIN+FR4+Gia1
15 ’ RESIN+FR4
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Kratak sadr`aj: U cilju pronala`enja bitnih strukturnih motiva potrebnih za interakciju sa a podjedinicom
Gi1 proteina klonirana su, eksprimirana i pre~i{}ena 4 fragmenta tre}e citoplazmati~ne petlje (CPL3) dopamin-
skog D2L receptora koji su dalje pripremljeni kao fuzioni proteini sa glutation-S-transferazom (GST). Interakcije su
kvantifikovane bojenom reakcijom za odre|ivanje aktivnosti GST. Postojanje kompleksa D2L-CPL3 fragment-
Gia1 je dokazano elektroforetskom analizom na SDS-poliakrilamidnom gelu (PAGE). Kd vrednosti za tri fragmenta
su bile vrlo sli~ne i u nmol/L opsegu koncentracija, dok je peptid koji predstavlja insert u dugom obliku dopamin-
skog D2 receptora posedovao oko 10 puta manji afinitet vezivanja za Gia1. Ovi rezultati mogu biti osnova za sin-
tezu novih terapeutskih agenasa koji bi delovali na nivou interakcije receptora i G proteina umesto na nivou vezi-
vanja liganda za receptor.
Klju~ne re~i: dopaminski D2L receptor, tre}a intracelularna petlja, sintetski peptid, sprega receptor/G pro-
tein.
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